Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price was up 12.5% during trading on Tuesday . The stock traded as high as $11.62 and last traded at $11.57. Approximately 43,273 shares traded hands during trading, a decline of 83% from the average daily volume of 247,602 shares. The stock had previously closed at $10.28.
Wall Street Analyst Weigh In
Several equities analysts have commented on MAZE shares. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 target price on the stock. Guggenheim restated a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a report on Wednesday, April 2nd. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Leerink Partners started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $25.67.
View Our Latest Stock Analysis on MAZE
Maze Therapeutics Stock Performance
The company's 50 day moving average price is $9.50.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund acquired a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $25,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics in the first quarter valued at approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics in the first quarter valued at approximately $57,000. Rhumbline Advisers bought a new position in Maze Therapeutics in the first quarter valued at approximately $80,000. Finally, Deutsche Bank AG bought a new position in Maze Therapeutics in the first quarter valued at approximately $98,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
